Evolus, Inc. Aktie News

Evolus, a global performance beauty company, raised $60m in its IPO in 2018. Its first and only commercial product, Jeuveau, is an injectable botulinum toxin Type A product that has been approved in the US and most European territories. Evolus has settled a lawsuit with AbbVie and is focused on taking on Botox in the commercial markets.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten offering price of $14.07 per share, which is equal to the closing price on Friday, March 8, 2024, before underwriting discounts and commissions. The gross proceeds from the offering to Evolus are expected to be app...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 11,355 shares of Evolus and an aggregate of 82,730 restricted stock units (RSUs) of the company's common stock to 8 newly hired non-executive emplo...

Evolus, Inc. (NASDAQ:EOLS ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Nareg Sagherian - VP and Head of Global Investor Relations and Corporate Communications David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research & Development Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Louise Chen - Cantor Fitzgerald Navann Ty -...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced its financial results for the fourth quarter and full year ended December 31, 2023. “2023 was a defining year for Evolus. We achieved record market share as the fastest growing toxin in the U.S. for the th...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will provide the data presented at IMCAS during its upcoming Earnings conference call on March 7th at 4:30 p.m. ET. Evolus remains on track for the global commercial launch of the first-generation Cold HA Te...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--To participate in the conference call, dial (877) 407-6184 or (201) 389-0877 or join the webcast on the Investor Relations page of the Evolus website.